• Target：
• LATS1/2

• Fields：
• >>Hippo signaling pathway;>>Hippo signaling pathway - multiple species

• Gene Name：
• LATS1/LATS2

• Protein Name：
• Serine/threonine-protein kinase LATS1/2

• Human Gene Id：
• 9113/26524

• Human Swiss Prot No：
• O95835/Q9NRM7

• Mouse Gene Id：
• 16798/50523

• Immunogen：
• The antiserum was produced against synthesized peptide derived from human LATS1/2 around the phosphorylation site of Thr1079/1041. AA range:1041-1090

• Specificity：
• Phospho-LATS1/2 (T1079/1041) Polyclonal Antibody detects endogenous levels of LATS1/2 protein only when phosphorylated at T1079/1041.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• IHC 1:100 - 1:300. ELISA: 1:20000.. IF 1:50-200

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• LATS1;WARTS;Serine/threonine-protein kinase LATS1;Large tumor suppressor homolog 1;WARTS protein kinase;h-warts;LATS2;KPM;Serine/threonine-protein kinase LATS2;Kinase phosphorylated during mitosis protein;Large tumor suppressor ho

• Molecular Weight(Da)：
• 125kD

• Background：
• The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatmen

• Function：
• catalytic activity:ATP + a protein = ADP + a phosphoprotein.,cofactor:Magnesium.,function:Tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDC2 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function.,PTM:Autophosphorylated and phosphorylated during M-phase of the cell cycle. Phosphorylated by STK3 at Ser-909 and Thr-1079, which results in its activation. Phosphorylated upon DNA damage, probably by ATM or ATR.,similarity:Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family.,similarity:Contains 1 AGC-kinase C-terminal domain.,similarity:Contains 1 protein kinase domain.,

• Subcellular Location：
• Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, spindle . Midbody . Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body . Localizes to the centrosomes throughout interphase but migrates to the mitotic apparatus, including spindle pole bodies, mitotic spindle, and midbody, during mitosis. .

• Expression：
• Expressed in all adult tissues examined except for lung and kidney.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs